The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Open accessAbstract
Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were designed to allow specific targeting of highly potent cytotoxic agents to tumor cells whilst sparing normal cells. Frequent toxicities that may be driven by any of the components of an ADC have been reported. There are currently more than 50 ADCs in active clinical development, and a further ∼20 that have been discontinued. For this review, the reported toxicities of ADCs were analysed, and the mechanisms for their effects are explored in detail. Methods to reduce toxicities, including dosing strategies and drug design, are discussed. The toxicities reported for active and discontinued drugs are important to drive the rational design and improve the therapeutic index of ADCs of the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Krop, I. E., Kim, S.-B., González-Martín, A., LoRusso, P. M., Ferrero, J.-M., Smitt, M., Yu, R., Leung, A. C. F., & Wildiers, H. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70178-0 · Cited by 724
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
Optimal and consistent protein glycosylation in mammalian cell culture
Hossler, P., Khattak, S. F., & Li, Z. J. (2009) · Glycobiology · doi:10.1093/glycob/cwp079 · Cited by 669
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., Jonas, M., Anderson, M. E., Setter, J. R., & Senter, P. D. (2015) · Nature Biotechnology · doi:10.1038/nbt.3212 · Cited by 557
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Jain, N., Smith, S. W., Ghone, S., & Tomczuk, B. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1657-7 · Cited by 459
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Advani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1900 · Cited by 336
Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., Patel, M. R., Sangha, R., Hagenbeek, A., Advani, R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70128-2 · Cited by 336
Tijink, B. M., Buter, J., de Bree, R., Giaccone, G., Lang, M. S., Staab, A., Leemans, C. R., & van Dongen, G. A. M. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0910 · Cited by 315
Mitosis is not a key target of microtubule agents in patient tumors
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228 · Cited by 314 · cited 2×
“More recent work shows that microtubule inhibitors may also disrupt non-dividing cells in interphase.(11) These findings provide explanation of how the microtubule inhibitors are cytotoxic to slowly replicating or non-dividing tumor cells.”
BackgroundCardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 311
Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
Eaton, J. S., Miller, P. E., Mannis, M. J., & Murphy, C. J. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2015.0064 · Cited by 276
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., & Slichenmyer, W. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.478 · Cited by 271
Williams, R. J., Tse, T., DiPiazza, K., & Zarin, D. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127242 · Cited by 226
Gibson, R. J., & Keefe, D. M. K. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0040-y · Cited by 218
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Uppal, H., Doudement, E., Mahapatra, K., Darbonne, W. C., Bumbaca, D., Shen, B.-Q., Du, X., Saad, O., Bowles, K., Olsen, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2093 · Cited by 218
Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., Smith, L., de Bono, J., Schwartz, G., Mays, T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.137 · Cited by 206 · cited 1×
“Neither compound has progressed further than Phase 1, possibly due to their minimal anti-tumor effects.(32,54)”
BackgroundRiechelmann, H., Sauter, A., Golze, W., Hanft, G., Schroen, C., Hoermann, K., Erhardt, T., & Gronau, S. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2007.10.009 · Cited by 198
Poon, K. A., Flagella, K., Beyer, J., Tibbitts, J., Kaur, S., Saad, O., Yi, J.-H., Girish, S., Dybdal, N., & Reynolds, T. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.09.003 · Cited by 198
Saleh, M. N., Sugarman, S., Murray, J., Ostroff, J. B., Healey, D., Jones, D., Daniel, C. R., LeBherz, D., Brewer, H., Onetto, N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2282 · Cited by 196
Yardley, D. A., Weaver, R., Melisko, M. E., Saleh, M. N., Arena, F. P., Forero, A., Cigler, T., Stopeck, A., Citrin, D., Oliff, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2959 · Cited by 190
Strop, P., Delaria, K., Foletti, D., Witt, J. M., Hasa-Moreno, A., Poulsen, K., Casas, M. G., Dorywalska, M., Farias, S., Pios, A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3274 · Cited by 182
McKoy, J. M., Angelotta, C., Bennett, C. L., Tallman, M. S., Wadleigh, M., Evens, A. M., Kuzel, T. M., Trifilio, S. M., Raisch, D. W., Kell, J., et al. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.07.005 · Cited by 180
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
Galsky, M. D., Eisenberger, M., Moore-Cooper, S., Kelly, W. K., Slovin, S. F., DeLaCruz, A., Lee, Y., Webb, I. J., & Scher, H. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0532 · Cited by 145
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Liu, J. F., Moore, K. N., Birrer, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw401 · Cited by 132
Tannir, N. M., Forero, A., Ramchandren, R., Pal, S. K., Ansell, S. M., Infante, J. R., de Vos, S., Hamlin, P. A., Kim, S. K., Whiting, N. C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0151-0 · Cited by 128
Dieras, V. C., Harbeck, N., Budd, G. T., Greenson, J. K., Guardino, A. E., Samant, M. K., Chernyukhin, N., Smitt, M. C., & Krop, I. E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.4999 · Cited by 126
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Annunziata, C. M., Kohn, E. C., LoRusso, P. M., Houston, N. D., Coleman, R. L., Buzoianu, M., Robbie, G. J., & Lechleider, R. J. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9801-2 · Cited by 121
Lhospice, F., Brégeon, D., Belmant, C., Dennler, P., Chiotellis, A., Fischer, E., Gauthier, L., Boëdec, A., Rispaud, H., Savard-Chambard, S., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500666j · Cited by 120
Weekes, C. D., Lamberts, L. E., Borad, M. J., Voortman, J., McWilliams, R. R., Diamond, J. R., de Vries, E. G. E., Verheul, H. M. W., Lieu, C. H., Kim, G. P., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0693 · Cited by 119
Gorovits, B., & Krinos‐Fiorotti, C. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1369-3 · Cited by 116
Govindan, S. V., Cardillo, T. M., Moon, S.-J., Hansen, H. J., & Goldenberg, D. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0586 · Cited by 115
Vaklavas, C., & Forero, A. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712443076 · Cited by 115
Hamblett, K. J., Kozlosky, C. J., Siu, S., Chang, W., Liu, H., Foltz, I. N., Trueblood, E. S., Meininger, D. P., Arora, T., Twomey, B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1078 · Cited by 110
Lapusan, S., Vídriales, M., Thomas, X., de Botton, S., Vekhoff, A., Tang, R., Dumontet, C., Morariu-Zamfir, R., Lambert, J. M., Ozoux, M., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9670-0 · Cited by 108
Bendell, J. C., Saleh, M. N., Rose, A. A. N., Siegel, P. M., Hart, L. L., Sirpal, S., Jones, S. F., Green, J., Crowley, E. M., Simantov, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5683 · Cited by 108
Zeuner, A., Signore, M., Martinetti, D., Bartucci, M., Peschle, C., & Maria, R. D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4303 · Cited by 107
Ribrag, V., Dupuis, J., Tilly, H., Morschhauser, F., Lainé, F., Houot, R., Haïoun, C., Copie‐Bergman, C., Varga, A., Lambert, J. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0580 · Cited by 105
Rupp, U., Schoendorf-Holland, E., Eichbaum, M. H. R., Schütz, F., Lauschner, I., Schmidt, P., Staab, A., Hanft, G., Huober, J., Sinn, H., et al. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32801403f4 · Cited by 99
Ott, P. A., Hamid, O., Pavlick, A. C., Kluger, H. M., Kim, K. B., Boasberg, P. D., Simantov, R., Crowley, E. M., Green, J. A., Hawthorne, T. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8115 · Cited by 97
EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
Lee, J., Han, H. D., Shahzad, M. M. K., Kim, S. W., Mangala, L. S., Nick, A. M., Lü, C., Langley, R. R., Schmandt, R. E., Kim, H., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp231 · Cited by 90
Thon, J. N., Devine, M. T., Begonja, A. J., Tibbitts, J., & Italiano, J. E. (2012) · Blood · doi:10.1182/blood-2012-04-420968 · Cited by 86
Sauter, A., Kloft, C., Gronau, S., Bogeschdorfer, F., Erhardt, T., Golze, W., Schroen, C., Staab, A., Riechelmann, H., & Hoermann, K. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.4.927 · Cited by 59
Doñate, F., Raitano, A. B., Morrison, K., An, Z., Capo, L., Aviña, H., Karki, S., Morrison, K. J. M., Yang, P., Ou, J. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1542 · Cited by 52
Kelly, K. R., Chanan-Khan, A. A., Heffner, L. T., Somlo, G., Siegel, D. S. D., Zimmerman, T. M., Karnad, A. B., Munshi, N. C., Jagannath, S., Greenberg, A. L., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4736.4736 · Cited by 48
Moskowitz, C. H., Fanale, M. A., Shah, B. D., Advani, R. H., Chen, R., Kim, S. Y., Kostić, A., Liu, T., Peng, J. Z., & Forero, A. (2015) · Blood · doi:10.1182/blood.v126.23.182.182 · Cited by 48
Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma
Berdeja, J. G. (2014) · Frontiers in bioscience · doi:10.2741/4202 · Cited by 46
Jagannath, S., Chanan-Khan, A., Heffner, L. T., Avigan, D., Zimmerman, T. M., Lonial, S., Lutz, R. J., Engling, A., Uherek, C., Osterroth, F., et al. (2011) · Blood · doi:10.1182/blood.v118.21.305.305 · Cited by 44
A phase 1 study of ABT-806 in subjects with advanced solid tumors
Cleary, J. M., Reardon, D. A., Azad, N. S., Gandhi, L., Shapiro, G. I., Chaves, J. M., Pedersen, M., Ansell, P. J., Ames, W., Xiong, H., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0234-6 · Cited by 41
Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody–drug conjugates
Sapra, P., Betts, A. M., & Boni, J. P. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.827405 · Cited by 30
Nabhan, C., Rundhaugen, L. M., Jatoi, M. N., Riley, M. B., Boehlke, L., Peterson, L. C., & Tallman, M. S. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh324 · Cited by 28
Petrylak, D. P., Vogelzang, N. J., Chatta, G. S., Fleming, M. T., Smith, D. C., Appleman, L. J., Hussain, A., Modiano, M., Singh, P., Tagawa, S. T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.7_suppl.144 · Cited by 25
Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Kollmannsberger, C., Redman, B. G., Sangha, R. S., Ernst, D. S., Пили, Р., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2503 · Cited by 25
Mita, M. M., Ricart, A. D., Mita, A. C., Patnaik, A., Sarantopoulos, J., Sankhala, K. K., Fram, R. J., Qin, A., Watermill, J., & Tolcher, A. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3062 · Cited by 24
Gan, H. K., Papadopoulos, K. P., Fichtel, L., Lassman, A. B., Merrell, R. T., van den Bent, M. J., Kumthekar, P., Scott, A. M., Pedersen, M., Gomez, E. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2016 · Cited by 21
Mega, A. E., Petrylak, D. P., Kantoff, P. W., Stephenson, J., Vogelzang, N. J., Dreicer, R., Shore, N. D., Stambler, N., Carpenito, J., D’Ambrosio, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4662 · Cited by 18
A phase I dose-escalation study of IMGN388 in patients with solid tumors.
Thompson, D. S., Patnaik, A., Bendell, J. C., Papadopoulos, K., Infante, J. R., Mastico, R. A., Johnson, D. H., Qin, A., O'Leary, J. J., & Tolcher, A. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3058 · Cited by 16
Borghaei, H., O’Malley, D. M., Seward, S. M., Bauer, T. M., Perez, R. P., Oza, A. M., Jeong, W., Michenzie, M. F., Kirby, M. W., Chandorkar, G., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5558 · Cited by 16
Moore, K. N., Ponte, J., LoRusso, P. M., Birrer, M. J., Bauer, T. M., Borghaei, H., O’Malley, D. M., Ruiz-Soto, R., Lutz, R., & Malik, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5571 · Cited by 16
Moore, K. N., Martin, L. P., Seward, S. M., Bauer, T. M., O’Malley, D. M., Perez, R. P., Oza, A. M., Jeong, W., Kirby, M. W., Zhou, Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5518 · Cited by 13
Treatment of Chemotherapy-Induced Nausea and Vomiting
Inrhaoun, H., Kullmann, T., Elghissassi, I., M’rabti, H., & Errihani, H. H. (2012) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-012-9401-6 · Cited by 12
Liu, J. F., Moore, K. N., Birrer, M. J., Berlin, S. T., Matulonis, U. A., Infante, J. R., Xi, J., Kahn, R., Wang, Y., Wood, K., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-290 · Cited by 12
Bardia, A., Vahdat, L. T., Diamond, J. R., Starodub, A., Moroose, R., Isakoff, S. J., Ocean, A. J., Berlin, J. D., Messersmith, W. A., Thomas, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1016 · Cited by 12
mTOR inhibition in T-cell lymphoma: a path(way) forward
Moskowitz, A. J., & Horwitz, S. M. (2015) · Blood · doi:10.1182/blood-2015-05-644724 · Cited by 8
Kennedy, D. A., Alley, S. C., Zhao, B., Feldman, E. J., O'Meara, M. M., & Sutherland, M. K. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ddt02-04 · Cited by 7
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Metadata
- Authors
- Donaghy, H.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2016-04-05
- Volume
- 8
- Issue
- 4
- Pages
- 659-671
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2315322079
- Cited by
- 495
- References
- 78
- FWCI
- 31.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.